FDA's Francis R.W. Godwin (CDER) and Kathleen Jones, PhD (CBER) detail a record pace of drug warning letters and the CGMP deficiencies most commonly cited in biologics facility inspections.
|Articles|July 20, 2020
Contact BioPharm International Editors
Listen
0:00 / 0:00
Key Takeaways
- BioPharm International's editorial team includes key figures like Christopher Cole and Susan Haigney, with specific contact details provided for communication.
- Contributing editors such as Cynthia A. Challener, PhD, and Siegfried Schmitt offer specialized expertise, enhancing the publication's content.
View contact information for the BioPharm International editorial team.
Advertisement
BioPharm International Editors
259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831
United States
Press Release and News Announcements
Send press releases to
Article/Submission Inquiries
Editorial Staff
Christopher Cole
Associate Editorial Director
Susan Haigney
Lead Editor
tel. 732.346.3045
Feliza Mirasol
Science Editor
tel. 732.346.3024
Patrick Lavery
Editor
tel. 609.716.7777
Contributing Editors/Columnists
Cynthia A. Challener, PhD
Contributing Editor
Siegfried Schmitt
Ask the Expert
Susan J. Schniepp
Ask the Expert
Subscription Support
Advertisement
Related to this article
Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.
FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
Inebilizumab (Uplizna) cut MG-ADL scores by 1.9 points versus placebo, supporting its approval in Japan for myasthenia gravis.
Regulatory approvals, trial data, and major licensing deals in 2026 are accelerating subcutaneous biologics, cutting patient burden and reshaping biopharma strategy.
Today’s biopharma news highlights GSK’s myeloma strategy, Insilico’s AI longevity research, and innovations that may improve future treatment outcomes.
As data volumes explode, clinical data harmonization, hybrid cloud, and AI are reshaping biopharma IT into the industry's core growth engine.
Insilico's Longevity Vaccines use circular mRNA to arm T cells against aging's earliest culprit cells, starting with immune rejuvenation.
Advertisement
Advertisement